Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
VYNE Therapeutics Inc. VYNE
$7.29
+$1.42 (19.43%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
25078407.00000000
-
week52high
9.90
-
week52low
2.00
-
Revenue
477000
-
P/E TTM
-1
-
Beta
1.53951700
-
EPS
-12.07000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 10 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 07 мая 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Harsch Mutya | D | 229144 | 1813 | 31 дек 2022 г. |
| Stuart Iain | D | 220252 | 1720 | 31 дек 2022 г. |
| Domzalski David | D | 1064290 | 10685 | 31 дек 2022 г. |
| Zeronda Tyler | D | 173005 | 354 | 31 дек 2022 г. |
| Domzalski David | A | 1074975 | 34705 | 30 ноя 2022 г. |
| Stuart Iain | D | 221972 | 1719 | 30 сент 2022 г. |
| Zeronda Tyler | D | 173359 | 353 | 30 сент 2022 г. |
| Domzalski David | D | 1040270 | 10683 | 30 сент 2022 г. |
| Harsch Mutya | D | 230957 | 1813 | 30 сент 2022 г. |
| BARBARI SHARON | A | 20500 | 20500 | 10 авг 2022 г. |
Новостная лента
VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
GlobeNewsWire
18 ноя 2022 г. в 08:00
BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, and management will host investor meetings on December 1, 2022.
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
10 ноя 2022 г. в 18:48
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 0% and 67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About VYNE Therapeutics Inc. (VYNE) Rating Upgrade to Buy
Zacks Investment Research
17 авг 2022 г. в 13:33
VYNE Therapeutics Inc. (VYNE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
GlobeNewsWire
18 мая 2022 г. в 08:00
BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will present at the HC Wainwright & Co. Global Investment Conference on May 25, 2022. Management will also be available for one-on-one meetings with investors.
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
12 мая 2022 г. в 19:34
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?